Applied BioCode (6598.TW) Stock Price

Applied BioCode Price

TWSE·CLOSED
23.80TWD-1.00 (-4.12 %)
Market closed

Revenue has compounded at 34.9% per year over the past 9 years to 343.07 M TWD. Applied BioCode's net margin stands at -76.0%, down from -34.6% several years earlier. The stock trades about 24% above its 52-week low.

Applied BioCode stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Applied BioCode over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Applied BioCode stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Applied BioCode's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Applied BioCode Stock Price History
DateApplied BioCode Price
7/14/202623.80 TWD
7/13/202624.80 TWD
7/10/202622.85 TWD
7/9/202622.85 TWD
7/8/202622.75 TWD
7/7/202622.95 TWD
7/6/202623.25 TWD
7/3/202623.05 TWD
7/2/202622.75 TWD
7/1/202622.50 TWD
6/30/202622.85 TWD
6/29/202622.85 TWD
6/26/202622.80 TWD
6/25/202622.90 TWD
6/24/202623.20 TWD
6/23/202623.45 TWD
6/22/202623.75 TWD
6/18/202624.15 TWD
6/17/202624.40 TWD
6/16/202624.40 TWD
6/15/202625.00 TWD
6/12/202624.60 TWD
6/11/202624.50 TWD
6/10/202624.90 TWD
6/9/202625.00 TWD
6/8/202624.50 TWD
6/5/202624.50 TWD
6/4/202624.50 TWD
6/3/202624.10 TWD
6/2/202624.30 TWD
6/1/202624.20 TWD
5/29/202624.75 TWD
5/28/202624.75 TWD
5/27/202624.95 TWD
5/26/202624.85 TWD
5/25/202624.50 TWD
5/22/202624.30 TWD
5/21/202624.30 TWD
5/20/202624.20 TWD
5/19/202624.65 TWD
5/18/202624.50 TWD
5/15/202624.35 TWD
5/14/202623.75 TWD
5/13/202624.15 TWD
5/12/202623.35 TWD
5/11/202622.70 TWD
5/8/202622.50 TWD
5/7/202622.60 TWD
5/6/202622.90 TWD
5/5/202622.55 TWD
5/4/202622.55 TWD
4/30/202621.45 TWD
4/29/202621.95 TWD
4/28/202621.90 TWD
4/27/202621.90 TWD
4/24/202621.95 TWD
4/23/202621.85 TWD
4/22/202622.15 TWD
4/21/202622.25 TWD
4/20/202622.70 TWD
4/17/202622.80 TWD
4/16/202622.90 TWD
4/15/202622.80 TWD
4/14/202622.60 TWD
4/13/202622.60 TWD
4/10/202622.00 TWD
4/9/202621.80 TWD
4/8/202622.80 TWD
4/7/202622.55 TWD
4/2/202623.10 TWD
4/1/202623.40 TWD
3/31/202622.65 TWD
3/30/202623.30 TWD
3/27/202623.35 TWD
3/26/202623.55 TWD
3/25/202624.15 TWD
3/24/202623.65 TWD
3/23/202624.25 TWD
3/20/202624.95 TWD
3/19/202625.00 TWD
3/18/202624.80 TWD
3/17/202624.60 TWD
3/16/202624.80 TWD
3/13/202625.05 TWD
3/12/202624.55 TWD
3/11/202625.30 TWD
3/10/202623.90 TWD
3/9/202623.60 TWD
3/6/202624.65 TWD
3/5/202624.50 TWD
2/26/202625.30 TWD
2/25/202624.55 TWD
2/24/202624.35 TWD
2/23/202624.50 TWD
2/11/202624.05 TWD
2/10/202624.05 TWD
2/9/202625.65 TWD
2/6/202623.35 TWD
2/5/202624.30 TWD
2/4/202624.40 TWD
2/3/202624.10 TWD
2/2/202623.60 TWD
1/30/202624.10 TWD
1/29/202624.05 TWD
1/28/202624.80 TWD
1/27/202624.15 TWD
1/26/202623.95 TWD
1/23/202623.60 TWD
1/22/202624.05 TWD
1/21/202623.45 TWD
1/20/202623.90 TWD
1/19/202624.50 TWD
1/16/202624.45 TWD
1/15/202624.60 TWD
1/13/202623.40 TWD
1/12/202624.25 TWD
1/9/202623.15 TWD
1/8/202623.05 TWD
1/7/202622.30 TWD
1/6/202622.40 TWD
1/5/202622.35 TWD
1/2/202622.00 TWD
12/31/202522.00 TWD
12/30/202522.00 TWD
12/29/202522.30 TWD
12/26/202522.05 TWD
12/24/202521.60 TWD
12/23/202522.00 TWD
12/22/202522.10 TWD
12/19/202521.50 TWD
12/18/202521.25 TWD
12/17/202521.10 TWD
12/16/202521.10 TWD
12/15/202521.25 TWD
12/12/202521.10 TWD
12/11/202521.40 TWD
12/10/202521.45 TWD
12/9/202521.30 TWD
12/8/202521.40 TWD
12/5/202521.55 TWD
12/4/202521.40 TWD
12/3/202521.65 TWD
12/2/202521.65 TWD
12/1/202521.75 TWD
11/28/202522.10 TWD
11/27/202521.70 TWD
11/26/202521.55 TWD
11/25/202521.35 TWD
11/24/202521.20 TWD
11/21/202521.20 TWD
11/20/202520.95 TWD
11/19/202520.55 TWD
11/18/202521.00 TWD
11/17/202521.00 TWD
11/14/202521.10 TWD
11/13/202521.25 TWD
11/12/202521.30 TWD
11/11/202521.85 TWD
11/10/202522.70 TWD
11/7/202523.10 TWD
11/6/202522.70 TWD
11/5/202522.70 TWD
11/4/202522.65 TWD
11/3/202522.80 TWD
10/31/202522.90 TWD
10/30/202523.00 TWD
10/29/202522.55 TWD
10/28/202523.05 TWD
10/27/202523.00 TWD
10/23/202523.10 TWD
10/22/202523.15 TWD
10/21/202523.00 TWD
10/20/202523.10 TWD
10/17/202523.00 TWD
10/16/202522.95 TWD
10/15/202522.85 TWD
10/14/202522.75 TWD
10/13/202523.00 TWD
10/9/202523.10 TWD
10/8/202522.70 TWD
10/7/202522.95 TWD
10/3/202522.55 TWD
10/2/202522.60 TWD
10/1/202523.30 TWD
9/30/202523.65 TWD
9/26/202523.60 TWD
9/25/202523.00 TWD
9/24/202522.65 TWD
9/23/202522.60 TWD
9/22/202522.45 TWD
9/19/202522.70 TWD
9/18/202522.95 TWD
9/17/202523.05 TWD
9/16/202523.10 TWD
9/15/202523.05 TWD
9/12/202523.15 TWD
9/11/202523.35 TWD
9/10/202523.35 TWD
9/9/202523.25 TWD
9/8/202521.40 TWD
9/5/202520.85 TWD
9/4/202522.00 TWD
9/3/202520.60 TWD
9/2/202519.70 TWD
9/1/202519.35 TWD
8/29/202519.60 TWD
8/28/202519.55 TWD
8/27/202519.55 TWD
8/26/202519.55 TWD
8/25/202519.60 TWD
8/22/202519.35 TWD
8/21/202519.35 TWD
8/20/202519.25 TWD
8/19/202519.30 TWD
8/18/202519.55 TWD
8/15/202519.55 TWD
8/14/202519.55 TWD
8/13/202519.50 TWD
8/12/202519.50 TWD
8/11/202519.50 TWD
8/8/202519.90 TWD
8/7/202520.00 TWD
8/6/202520.15 TWD
8/5/202520.05 TWD
8/4/202519.80 TWD
8/1/202519.90 TWD
7/31/202519.60 TWD
7/30/202519.70 TWD
7/29/202519.70 TWD
7/28/202519.95 TWD
7/25/202520.10 TWD
7/24/202520.20 TWD
7/23/202520.10 TWD
7/22/202519.90 TWD
7/21/202520.45 TWD
7/18/202520.35 TWD
7/17/202520.20 TWD
7/16/202520.00 TWD
Access this data via the Eulerpool API
Get Free API Key

Applied BioCode Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
36.90 M TWD
-267.88 M TWD
-268.31 M TWD
Jan 1, 2019
104.69 M TWD
-275.07 M TWD
-280.07 M TWD
Jan 1, 2020
299.02 M TWD
-133.51 M TWD
-103.50 M TWD
Jan 1, 2021
319.96 M TWD
-164.94 M TWD
-165.20 M TWD
Jan 1, 2022
390.30 M TWD
-192.60 M TWD
-184.73 M TWD
Jan 1, 2023
395.17 M TWD
-186.70 M TWD
-164.20 M TWD
Jan 1, 2024
343.07 M TWD
-277.91 M TWD
-260.81 M TWD
Jan 1, 2025 (e)
510.00 M TWD
-182.58 M TWD
-155.28 M TWD

Applied BioCode Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 15, 2026, 10:57 AM
 
REVENUEM TWD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM TWD
NET INCOMEM TWD
NET INCOME GROWTH%
SHARESM
20152016201720182019202020212022202320242025e
23.0011.0026.0036.00104.00299.00319.00390.00395.00343.00510.00
–-52.17136.3638.46188.89187.506.6922.261.28-13.1648.69
26.0936.3630.7744.4450.0064.5559.2560.0067.8559.1859.18
6.004.008.0016.0052.00193.00189.00234.00268.00203.00301.84
-21.00-183.00-263.00-268.00-280.00-103.00-165.00-184.00-164.00-260.00-155.00
–771.4343.721.904.48-63.2160.1911.52-10.8758.54-40.38
27.3344.2247.2152.9964.2777.5781.7087.5287.5490.6290.62
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Applied BioCode generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Applied BioCode retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Applied BioCode's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Applied BioCode has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Applied BioCode's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Applied BioCode stock margins

The Applied BioCode margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Applied BioCode. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Applied BioCode.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
45.34 %
-725.88 %
-727.04 %
Jan 1, 2019
50.59 %
-262.74 %
-267.52 %
Jan 1, 2020
64.72 %
-44.65 %
-34.61 %
Jan 1, 2021
59.18 %
-51.55 %
-51.63 %
Jan 1, 2022
60.00 %
-49.35 %
-47.33 %
Jan 1, 2023
68.01 %
-47.25 %
-41.55 %
Jan 1, 2024
59.46 %
-81.01 %
-76.02 %
Jan 1, 2025 (e)
59.46 %
-35.80 %
-30.45 %

Applied BioCode Stock Revenue, EBIT, Earnings per Share

The Applied BioCode earnings per share therefore indicates how much revenue Applied BioCode has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.70 TWD
-5.06 TWD
-5.06 TWD
Jan 1, 2019
1.63 TWD
-4.28 TWD
-4.36 TWD
Jan 1, 2020
3.85 TWD
-1.72 TWD
-1.33 TWD
Jan 1, 2021
3.92 TWD
-2.02 TWD
-2.02 TWD
Jan 1, 2022
4.46 TWD
-2.20 TWD
-2.11 TWD
Jan 1, 2023
4.51 TWD
-2.13 TWD
-1.88 TWD
Jan 1, 2024
3.79 TWD
-3.07 TWD
-2.88 TWD
Jan 1, 2025 (e)
5.63 TWD
-2.01 TWD
-1.71 TWD

Applied BioCode business model & stock analysis

Applied BioCode Corp is a California-based company that focuses on the development and marketing of diagnostic instruments and tests. The company was founded in 2004 by an experienced management team and has since developed a number of groundbreaking technologies to improve the diagnosis of diseases such as cancer, infectious diseases, and autoimmune diseases. The business model of Applied BioCode Corp is based on the development of innovative diagnostic instruments and test systems based on proprietary technologies. The company has a strong partnership with a leading manufacturer of diagnostic automation systems, allowing a wide range of tests for various diseases to be offered. Applied BioCode Corp also works closely with leading research and development organizations to leverage the latest insights in the field of diagnostics. One of the divisions of Applied BioCode is molecular diagnostics, which is an essential component of modern medicine. Molecular diagnostics enables the detection of genetic changes and deviations related to diseases. Applied BioCode's technology allows for rapid and precise identification of pathogens in clinical samples such as blood, urine, and tissue samples. Another important area for Applied BioCode is infectious disease diagnostics. The company has developed a range of test systems based on a variety of infectious diseases such as influenza, tuberculosis, and sexually transmitted diseases such as chlamydia and gonorrhea. These tests can be performed individually or as a group to facilitate disease diagnosis and improve treatment. Applied BioCode also offers tests for the detection of oncological markers. These tests are crucial for the early detection of cancer and monitoring the treatment of cancer patients. Applied BioCode's technology enables rapid and precise identification of cancer cells in blood or tissue, which can improve the effectiveness of treatment. Another important product of Applied BioCode is the BioCode Analyzer, an automated diagnostic instrument. The BioCode Analyzer is a high-throughput system capable of performing multiple tests simultaneously. The analyzer is equipped with a disposable chip that allows for quick and easy diagnosis. This makes the BioCode Analyzer a powerful tool for laboratory automation, providing fast and accurate diagnosis for a variety of diseases. Applied BioCode is also dedicated to researching and developing new technologies. The company has an active pipeline of new products and technologies to further improve diagnostic accuracy and the number of feasible tests. Applied BioCode is also developing new applications for its technologies to improve the diagnosis and treatment of diseases in various ways. In summary, Applied BioCode Corp plays an important role in the field of diagnostic technology. The company has developed a wide range of innovative diagnostic tests and instruments that enable diseases to be quickly and accurately detected. With its strong partnership with leading diagnostic automation system manufacturers and research organizations, Applied BioCode will continue to stay at the forefront and improve diagnostic practice.

Applied BioCode SWOT Analysis

Strengths

Applied BioCode Corp has a strong and experienced team of scientists and researchers, enabling them to develop innovative products and solutions for the healthcare industry. The company has a diverse product portfolio, offering a range of diagnostic tests and systems to cater to various medical needs. Their advanced technology and automated systems provide accurate and efficient results, enhancing patient care.

Weaknesses

One of the weaknesses of Applied BioCode Corp is its relatively limited market presence compared to some competitors. They may face challenges in establishing themselves as a recognized brand in the highly competitive healthcare industry. Additionally, the company's dependency on third-party suppliers for certain components or materials may pose a risk to their supply chain management.

Opportunities

Applied BioCode Corp has opportunities to expand its market reach by targeting emerging markets and exploring collaborations with strategic partners worldwide. With the growing demand for personalized medicine and precision diagnostics, the company can further capitalize on its technology and expertise. They can also leverage advancements in digital health and data analytics to enhance their product offerings and improve patient outcomes.

Threats

The healthcare industry is subject to rigorous regulations and standards, which can pose challenges for companies like Applied BioCode Corp. Compliance with these regulations and obtaining necessary approvals for their products can be time-consuming and costly. Additionally, the company faces competition from established players in the diagnostic industry, who may have greater resources and market presence.

Applied BioCode Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Applied BioCode historical P/E ratio, EBIT multiple, and P/S ratio

Applied BioCode annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Applied BioCode shares outstanding

The number of shares of Applied BioCode was 90.62 M in 2025. This indicates how many shares Applied BioCode is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
52.99 M Stocks
Jan 1, 2019
64.27 M Stocks
Jan 1, 2020
77.57 M Stocks
Jan 1, 2021
81.70 M Stocks
Jan 1, 2022
87.52 M Stocks
Jan 1, 2023
87.54 M Stocks
Jan 1, 2024
90.62 M Stocks
Jan 1, 2025 (e)
90.62 M Stocks
Price targets and forecasts for Applied BioCode are not yet available.

Applied BioCode shareholder structure

% Name
9.73018%
Hsu (Fu-Lung)
Hsu (Fu-Lung)
9.16736%
Maxwell Sensors Incorporation
Maxwell Sensors Incorporation
3.94085%
Eureka BioVenture Partners
Eureka BioVenture Partners
3.06682%
GVT Fund L.P.
GVT Fund L.P.
3.01164%
Celerus Diagnostics
Celerus Diagnostics
2.48303%
Cathay Venture Inc.
Cathay Venture Inc.

Applied BioCode Executives and Management Board

JL

Mr. Jia-Long Lee

Chairman of the Board · since 2016

ZH

Mr. Zohn-Zen Ho

Founder, Chief Technology Officer, General Manager, Director · since 2008

LH

Mr. Liang-Kai Huang

Chief Financial Officer, Corporate Governance Officer

MA

Mr. Michael Aye

Vice President-Molecular Products

DW

Mr. Donald Wong

Vice President-Productions

Frequently asked questions about Applied BioCode

The business model of Applied BioCode Corp is centered around providing innovative molecular diagnostics solutions. They specialize in the development, manufacture, and commercialization of barcode technology-based multiplex testing systems for diagnostics laboratories. With their proprietary BioCode-1000 system, they offer a cost-effective and scalable solution for high-throughput testing of various diseases such as cancer, infectious diseases, and genetic disorders. Applied BioCode Corp aims to improve patient outcomes by delivering accurate and timely diagnostic results to healthcare professionals. Their advanced technology, coupled with a commitment to continuous innovation, positions them as a leading player in the field of molecular diagnostics.

All fundamentals and in-depth analysis of Applied BioCode

Our stock analysis for Applied BioCode stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Applied BioCode. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Applied BioCode Stock
Applied BioCode Revenue→
Applied BioCode Stock
Applied BioCode Net Income→
Applied BioCode Stock
Applied BioCode P/E→
Applied BioCode Stock
Applied BioCode P/S→
Applied BioCode Stock
Applied BioCode EBIT→
Applied BioCode Stock
Applied BioCode Dividend→
Applied BioCode Stock
Applied BioCode Directors Dealings→
Applied BioCode Stock
Applied BioCode Stocks→
Applied BioCode Stock
Applied BioCode Market capitalization→
Applied BioCode Stock
Applied BioCode Debt→
Applied BioCode Stock
Applied BioCode Liabilities→
Applied BioCode Stock
Applied BioCode Equity→
Applied BioCode Stock
Applied BioCode AAQS→
Applied BioCode Stock
Applied BioCode Employees→
Applied BioCode Stock
Applied BioCode ROE→
Applied BioCode Stock
Applied BioCode ROA→
Applied BioCode Stock
Applied BioCode ROCE→
Applied BioCode Stock
Applied BioCode News→
Applied BioCode Stock
Applied BioCode Analyst Price Targets→

Health Stocks

Applied BiosciencesAppili TherapeuticsAprea TherapeuticsApollomicsAprilBio CoApollo Hospitals EnterpriseAprogen BiologicsAPOLLO BioWellnessAPT MedicalApogee TherapeuticsAptaBio TherapeuticsApimeds Pharmaceuticals USAll Stocks A–Z →